2010-2020年头颈癌试验中种族和民族报告不足与代表性不足:一项系统综述
该研究系统检索2010至2020年发表的及在ClinicalTrials.gov注册的头颈癌临床试验,共纳入155项试验。结果显示仅89项(57%)报告了种族或民族,且与监测、流行病学和最终结果(SEER)数据相比,试验中黑人患者(10% vs 8%)和亚裔或太平洋岛民患者(6% vs 2%)比例更低。作者认为参与人群未充分反映美国头颈癌人口学特征,限制了试验结果的推广性。
要点
- 155项头颈癌试验中仅89项(57%)报告了种族或民族,81项(52%)按美国人口普查局分类报告详细分类。
- 后半十年发表的试验更可能报告种族或民族(比值比2.78;95%CI 1.33-5.80),2019年最高(30项中24项[80%])。
- 与SEER数据相比,试验中黑人患者(10% vs 8%)和亚裔或太平洋岛民患者(6% vs 2%)比例更低。
核心结论
- 过去十年近一半头颈癌试验未报告参与者种族或民族,黑人和亚裔或太平洋岛民患者参与不足,限制结果推广性并加剧种族健康差异。
研究设计与样本
- 系统综述,系统检索2010至2020年发表的试验及ClinicalTrials.gov注册研究,从3973项研究中经标题、摘要和全文筛选纳入155项试验提取患者人口学数据。
主要发现
- 155项研究中仅89项(57%)报告种族或民族,仅81项(52%)按美国人口普查局分类方案报告详细分类。
- 后半十年发表的试验更可能报告种族或民族(比值比2.78;95%CI 1.33-5.80),2019年报告比例最高(30项中24项[80%]),其次为2020年(29项中20项[69%])。
- 治疗性放化疗试验报告种族或民族比例最高(12项中11项[92%]),其次为支持治疗药物试验(31项中22项[71%])和治疗性化疗试验(48项中28项[58%])。
- 与SEER数据相比,临床试验中黑人患者比例更低(10% vs 8%),亚裔或太平洋岛民患者比例也更低(6% vs 2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is substantial evidence demonstrating racial disparities in the survival outcomes of patients with head and neck cancer. The reporting and representation of race and ethnicity in cancer trials is crucial for generalizability of trial results to patient care and reduction of racial health disparities in head and neck cancers. Racial disparities in oncologic outcomes across various therapeutic interventions may only manifest when diverse races are appropriately represented in trials. OBJECTIVE: To characterize the reporting and representation of race and ethnicity in head and neck cancer clinical trials. EVIDENCE REVIEW: A systematic search of published trials and those available on ClinicalTrials.gov was conducted to identify 3973 studies from 2010 to 2020. Title, abstract, and full-text review yielded 155 trials for data extraction of patient demographics. Year of publication, type of intervention, publication source, and funding source were also collected. Race and ethnicity data were compared with Surveillance, Epidemiology, and End Results (SEER) Program cancer registry data. FINDINGS: Of the 155 included studies, only 89 (57%) reported race or ethnicity. Only 81 (52%) of the studies reported detailed classification of race or ethnicity per the US Census Bureau classification scheme. Race and ethnicity reporting varied considerably with year of publication, type of intervention, data source, and funding source. Studies in the latter half of the decade were more likely to report race or ethnicity (odds ratio, 2.78; 95% CI, 1.33-5.80), with the highest number in 2019 (24 of 30 [80%] trials), followed by 2020 (20 of 29 [69%] trials). Among the possible interventions, trials on therapeutic chemoradiation most frequently reported race or ethnicity (11 of 12 [92%]), followed by supportive drug trials (22 of 31 [71%]), and then therapeutic chemotherapy trials (28 of 48 [58%]). When compared with SEER data, race and ethnicity distribution in clinical trials showed fewer Black patients (10% vs 8%) and Asian or Pacific Islander patients (6% vs 2%). CONCLUSIONS AND RELEVANCE: In this systematic review, nearly half of head and neck cancer trials in the past decade did not report the race or ethnicity of participants. Participation of Black and Asian or Pacific Islander patients does not adequately reflect the US population's head and neck cancer demographics, limiting the generalizability of trial results and adding to racial health disparities in patients with head and neck cancers.
引用
- Sauer AB, Daher GS, Lohse CM, et al. Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020: A Systematic Review. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 35653143. doi:10.1001/jamaoto.2022.1028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。